BioLineRX
BLRX
34 hedge funds and large institutions have $15.7M invested in BioLineRX in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
31% more funds holding
Funds holding: 26 → 34 (+8)
0.33% less ownership
Funds ownership: 5.36% → 5.03% (-0.33%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
77% less capital inflows, than outflows
Capital inflows: $572K | Capital outflows: $2.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETF Managers Group
Summit,
New Jersey
|
+$134K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$99.2K |
| 3 |
Menta Capital
San Francisco,
California
|
+$61.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$49.1K |
| 5 |
Renaissance Technologies
New York
|
+$49.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Senvest Management
New York
|
-$2.35M |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
-$33K |
| 3 |
Focused Wealth Management
Newburgh,
New York
|
-$27.9K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$24.1K |
| 5 |
Next Financial Group
Houston,
Texas
|
-$24.1K |
BLRX Hedge Fund Activity: Q4 2018 in Review
34 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2018, worth a combined $15.7M — down 62% from $41M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BLRX positions and 1 closed out — a net gain of 8 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was ETF Managers Group, adding an estimated $134K. The largest seller was Senvest Management, cutting an estimated $2.35M.
- 34 institutional investors held BioLineRX (BLRX) as of Q4 2018, up from 26 in Q3 2018.
- Funds reported $15.7M of BioLineRX stock for Q4 2018, down 62% quarter-over-quarter.
- 9 funds opened new BioLineRX positions in Q4 2018 and 1 closed out, a net change of +8 holders.
- The largest BioLineRX buyer in Q4 2018 was ETF Managers Group, an estimated $134K added.
- The largest BioLineRX seller in Q4 2018 was Senvest Management, an estimated $2.35M sold.
Based on aggregated 13F filings for Q4 2018.